**Core Concept**
The question is testing the student's knowledge of newer monoclonal antibodies used in the treatment of rheumatoid arthritis. Monoclonal antibodies are a class of medications that target specific proteins involved in the inflammatory process, thereby reducing joint damage and improving symptoms in patients with rheumatoid arthritis.

**Why the Correct Answer is Right**
The newer monoclonal antibody approved for rheumatoid arthritis is Tocilizumab. Tocilizumab works by inhibiting the interleukin-6 (IL-6) receptor, a key cytokine involved in the inflammatory cascade. IL-6 is a pro-inflammatory cytokine that promotes the production of other inflammatory mediators, such as tumor necrosis factor-alpha (TNF-alpha) and interleukin-1 beta (IL-1β). By blocking the IL-6 receptor, Tocilizumab reduces the production of these inflammatory mediators, resulting in a decrease in joint inflammation and damage.

**Why Each Wrong Option is Incorrect**
* **Option A:** This option is incorrect because it is not a monoclonal antibody approved for rheumatoid arthritis.
* **Option B:** This option is incorrect because it is a different type of medication used to treat rheumatoid arthritis, such as a disease-modifying antirheumatic drug (DMARD).
* **Option C:** This option is incorrect because it is a biologic medication used to treat a different condition, such as psoriasis.

**Clinical Pearl / High-Yield Fact**
Tocilizumab is a useful option for patients with rheumatoid arthritis who have failed to respond to traditional DMARDs or biologics, such as TNF inhibitors. It is also used in combination with other medications to enhance its effectiveness.

**Correct Answer:** C. Tocilizumab